( 您好!臺灣時間:2021/07/25 02:17
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::


研究生(外文):Li-Fang Huang
論文名稱(外文):Synthesis and Biological Evaluation of 6-Substituted Phenanthridine Derivatives
指導教授(外文):Cherng-Chyi Tzeng
  • 被引用被引用:0
  • 點閱點閱:83
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
從芸香科植物中萃取出喹啉之生物鹼具有抗癌、抗菌、抗濾過性病毒等生物活性。融入含雜環芳香化合物具有一個平面結構,因這種平面結構能夠嵌入去氧核醣核酸中,以達抑制基因複製的效果,因此本研究主要合成phenanthridine在6位碳原子上含有苯胺及脂肪胺類化合物取代基團並探討其抗細胞增生活性。由實驗結果顯示其對各種癌細胞具有專一性和選擇性,尤其以化合物 N1,N1-dimethyl- N3-(phenanthridine-6-yl)propane-1,3-diamine (37),和N1-(3,8-dinitrophenanthridin-6-yl)-N2,N2-dimethylethane-12-diamine (46),和N1-(3,8-dinitrophenanthridin-6-yl)-N3,N3-dimethylpropane-1,3-diamine (47) ,和3,8-dinitro-N-(2-(piperazin-1-yl)ethyl)phenanthridin-6-amine (48) ,3,8-dinitro-6-(piperazin-1-yl)phenanthridine (53),和 6-(3-methylpiperazin-1-yl)-3,8-dinitrophenanthridine (57),和 6-(1,4-diazepan-1-yl)3,8-dinitrophenanthridine (58),和1-(3,8-dinitrophenanthridin-6-yl)piperidin-4-amine (59) ,此八種化合物對乳癌細胞 (MCF-7) 與肺癌細胞 (NCI-H460) 及中樞神經癌細胞 (SF-268) 等都有最佳的活
性,尤其對肺癌細胞 (NCI-H460) 的效果更佳。
The quinoline alkaloids isolated from the Rutaceae family of plants have various biological activities such as anticancer, antibacterial and antiviral effects. Polycondensed heterocyclic aromatic compounds having a planar structure can intercalate into DNA to inhibit the replication. The derivatives of phenanthridine were synthesized by changing the substitutent at C6, such as aniline group and aliphatic amines, and evaluated for their activities against the growth of various canner cells. Results indicated compounds of N1,N1-dimethyl-N3-(phenanthridine-6-yl)-propane-1,3-diamine (37), N1-(3,8-dinitrophenanthridin-6-yl)-N2,N2-dimethylethane-1,2-diamine (46), N1-(3,8-dinitrophenanthridin-6-yl)-N3,N3-dimethylpropane-1,3-diamine (47), 3,8-dinitro-N-(2-(piperazin-1-yl)-ethyl)phenanthridin-6-amine (48), 3,8-dinitro-6-(piperazin-1-yl)phenanthridine (53), 6-(3-methylpiperazin-1-yl)-3,8-dinitrophenanthridine (57), 6-(1,4-diazepan-1-yl)-3,8-dinitrophenanthridine (58), 1-(3,8-dinitrophenanthridin-6-yl)piperidin-4-amine (59) exhibit good inhibition on the breast cancer cell MCF-7, lung cancer cell NCI-H460 and CNS cancer cell SF-268. These compounds were especiallt active against the growth of lung cancer cell NCI-H460.
中文摘要 ---------------------------------------2
英文摘要 ---------------------------------------3
一、實驗方式 -------------------------------25
二、活性結果與討論 -------------------------25
一、溶劑及處理過程 -------------------------28
二、儀器及試藥 -----------------------------28
三、各化合物的製備 -------------------------32
伍、參考文獻 -----------------------------------60
1.Swanton, C. Cell-cycle targeted therapies. Lancet Oncol. 2004, 1, 27-36.
2.Dynlacht, B. D. Regulation of transcription by proteins that control the cellcycle. Nature 1997, 389, 149-152.
3.Zhou, B. B.; Elledge, S. J. The DNA damage response: putting checkpoints in perspective. Nature 2000, 408, 433-439.
4.Shapieo, G. I.; Harper, J. W. Anticancer drug targets: cell cycle and checkpoint control. J. Clin. Invest. 1999, 104, 1645-1653.
5.Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem. 1996, 65, 635-692.
6.Laurence, H. H. DNA and its associated processies as targets cancer therapy. Nat. Rev. Cancer 2002, 2, 188-200.
7.Hirota, M.; Fujiwara, T.; Mineshita, S.; Sugiyama, H.; Teraoka, H., Distamycin A enhamces the cytotoxicity of duocarmycin A and suppresses duocarmycin A-induced apoptosis in human lung carcinoma cells. Int. J. Biochem. Cell Biol. 2007, 39, 988-996.
8.Wang, Z.; Zimmer, C.; Lown, J. W.; Knippers, R. Effects of bifunctional netropsin-related minor groove-binding ligands on mammalian type I DNA topoisomerase. Biochem. Pharmacol. 1997, 53, 309-316.
9.Riou, J-F,; Grondard, L.; Naudin, A.; Bailly, C. Effects of two distamycin-ellipticine hybrid molecules on topoisomerase I and Ⅱmediated DNA cleavage: relation to cytotoxicity. Biochem. Pharmacol. 1995, 50, 424-428.
10.Braña, M. F.; Cacho, M.; Gradillas, A.; Pascual-Teresa, B. d; Ramos, A.; Intercalators as anticancer drugs. Curr. Pharm. Des. 2001, 7, 1745-1780.
11.Tuteja, N.; Phan, T-N.; Tuteja, R.; Ochem, A.; Falaschi, A. Inhibition of DNA unwinding and ATPase activities of human DNA helicase Ⅱby chemotherapeutic agents. Biochem Bioph. Res. Co. 1997, 236, 636-640.
12.Jain, K. K. Evaluation of mitoxantrone for the treatment of multiple sclerosis. Expert Opin Inv. Drug 2000, 9, 1139-1149.
13.Galloway, S. M.; Miller, J. E.; Armstrong, M. J.; Bean,C. L.; Skopek, T. R.; Nichols, W. W. DNA synthesis inhibition as an indirect mechanism of chromosome aberrations: comparison of DNA-reactive and non-DNA-reactive clastogens. Mutation Res. 1998, 400, 169-186.
14.Basak, J. On the nature of adapive response induced by mitomycin c in Vibrio choleraeOGAWA 154 Cells. Biochem. Bioph. Res. Co. 1996, 220,509-514.
15.Reddy, B. S. P.; Sondhi, S. M.; Lown, J. W. Synthetic DNA minor groove-binding drugs. Pharmacol. Therapeut. 1999,84,1-111.
16.Buschini, A.; Alessandrini, A.; Martino, A.; Pasini, L.; Rizzoli, V.; Carlo-Stella, C.; Poli, P.; Rossi, C.; Bleomycin genotoxicity and amifostine (WR-2721) cell protection in normal leukocytes vs. K562 tumoral cells. Biochem. Pharmacol. 2002, 63, 967-975.

17.Lefterov, I. M.; Koldamova, R. P.; King, J.; Lazo, J. S.; The C-terminus of human bleomycin hydrolase is required for protection against bleomycin-induced chromosoml damage. Mutation Res. 1998, 421, 1-7.
18.Loth stein, L; Israel, M.; Sweatman T. W. Anthracycline drug targeting: cytoplasmic versus nuclear - a fork in the road. Drug Resiut. Update 2001, 4, 169-177.
19.Smorenburg, C. H.; Sparreboom, A.; Bontenbal, M.; Verweij, J. Combination chemotherapy of the taxanes and antimetabolites: its use and limitations. Eur. J. Cancer 2001, 37, 2310-2323.
20.Moscow J. A.; Johnston P. G.; Cole, D.; Poplack, D. G.; Cowan, K. H. Characterization of cross-resistance to methotrexate in a human breast cancer cell line selected for resistance to melphalan. Biochem. Pharmacol. 1995, 49, 1069-1078.
21.Inaba, M.; Tanaka, T.; Sawada, H. Increased sensitivity to long-term 5-Fluorooracil exposure of human colon cancer HT-29 cells resistant to short-term exposure. Jpn. J. Cancer Res. 1998, 89, 323-327.
22.Pommier, Y.;Redon, C.;Rao, V. A.; Seiler, J. A.; Sordet, O.; Takemura, H.; Antony, S.; Meng, L. H.; Liao, Z. Y.;Kohihagen, G.;Zhang, H. L.;Kohn, K.W. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutation Res. 2003, 532, 173-203.
23.Hande, K. R. Etoposide: four decades of development of topoisomerase Ⅱinhibitor. Eur. J. Cancer 1998, 34, 1514-1521.

24.Kluza, J.; Lansiaux, A.; Wattez, N.; Mahieu, C.; Osheroff, N.;Bailly, C. Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. Cancer Res. 2000, 60, 4077-4084.
25.Stone, A. A.; Chambers, T. C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp. Cell Res. 2000, 254, 110-119.
26.Watanabe, T.; Inaba, M.; Sugiyama, Y. Saturable process involved in active efllux of vincristine as a mechanism of multidrug resistance in P388 leukemia cells. Pharmaceut. Res. 1989, 6, 690-696.
27.Jordan, M. A.; Thowar, D.; Wilson. L. Mechanism of inhibition of cell proliferation by vinca alkaloids. Cancer Res. 1991, 51, 2212-2222.
28.Seidman, R.; Gitelman, L.; Sagi, O.; Horwitz, S.B.; Wolfson, M. The role of ERK 1/2 and p38 MAP-kinase pathways in taxol-induced apoptosis in human ofarian carcinoma cells. Exp. Cell Res. 2001, 268, 84-92.
29.Petrylak, D. P. Chemotherapy for advanced hormone refrsctory prostate cancer. Urology. 1999, 54, 30-35.
30.Gottardis, M. M.; Jordan, V. C. Antitumor actions of keoxifene and tamoxifen in the N-nitrosomethylurea-induced rat mammary carcinoma model. Cancer Res. 1987, 47, 4020-4024.
31.Wittliff, J. L. Steroid-hormone receptors in breast cancer. Cancer 1984, 53, 630-643.

32.Teicher, B. A. Molecular targets and cancer therapeutics: discovery, developmemt and clinical validation. Drug Resist. Update 2000, 3, 67-73.
33.Rosa, D. D.; Ismael, G.; Laog, L. D.; Awada, A. Molecular-targeted therapies: Lessons from years of clinical development. Cancer Treat. Rev. 2008, 34, 61-80.
34.Marloney, D. G. Preclinical and phase ⅠandⅡtrials of rituxinab, Semin. Oncol. 1999, 26, 74-78.
35.Johnson, D. H. Gefitinib(Iressa) trials in non-small cell lung cancer. Lung cancer 2003, 41, 23-28.
36.Alexander, H.; Hopfner, M.; Barabara, V.; Schuppan, D.; Scherubl, H. Sorafenib alone or as combination therapy for growth control of cholangiocarcinona. Biochem. Pharmacol. 2007, 73, 1308-1317.
37.Sugino, A.; Peebles, C. L.; Kreuzer, K. N.; Cozzarelli, N. R. Mechanism of Action of Nalidixic Acid: Purification of Escherichia coil nalA Gene Product and its Relationship to DNA Gyrase and a Nevel Nicking-closing Enzyme.Proc. Natl. Acad. Sci.U.S.A. 1977, 74, 4767-4771.
38.Gellert, M.;mizuuchi, K.; O'Dea, M. H.;Itog, T.; Tomizawa, J. I. Nalidixic Acid Resistence: A Second Genetic Character Involoved in
DNA Gyrase Activity. Proc. Natl. Acad. Sci. U.S.A. 1977, 74, 4772.
39.Haemers,A.; Leysen, D. C.; Bollaert, W.; Zhang, M.; Pattyn, S. R. Influence of N-Substitution of Antimycobacterial Activity of Ciprofloxacin. Antimicrob. Agents. Chemother. 1990, 34, 496-497.

40.Devraj, R.; Barrett, J. F.; Fernandez, J. A.; Katzenellenbogen, J. A.; Cushman, M. Design, Synthesis, and Biological Evalauation of Ellipticine-Estradiol Conjugates. J. Med. Chem. 1996, 39, 3367-3374.
41.Denny, W. A.; Atwell, G. J.; Cain, B. F. Potential Antitumor Agents. 26. Anionic Congeners of the 9-Anilinoacridines. J. Med. Chem. 1978, 21, 5-10.
42.Denny, W. A.; Cain, B. F.; G. J.; Hansch, C.; Panthananiclcal, A.; Leo, A. Potential Antitumor Agents. 26. Quantutative Relationships between Experimental Antitumor Activity, Toxicity, and Structure for the General Class of the 9-Anilinoacridine Antitumor Agents. J. Med. Chem. 1982, 25, 276-315.
43.Gamage, S. A.; Figgitt, D. P.; Wojcik, S. J.; Ralph, R. K.; Ransijn, A.; Jacques, M.; Yardley, V.; Snowdon, N.; Croft, S. L.; Denny, W. A. Structure-Activity Reiationships for the Antileishmanial and Antitrypanosomal Activities of 1’-Substituted 9-Anilinoacridines J. Med. Chem. 1997, 40, 2634-2642.
44.Atwell, G. J.; Cain, B. F.; Seelye, R. N. Potential Antitumor Agents. 12. 9-Anilinoacridines. J.Med. Chem. 1972, 15, 611-615.
45.Su, T. L.; Chou, T. C.; Kim, J. Y.; Huang, J. T.; Ciszewska, G.; Ren, W. U.; Otter, G. M.; Sirotnak, F. M.; Watanabe, K. A. 9-Substituted Acridine Derivatives With Long Half-Life and Potent Antitumor Activity; Synthesis and Structure-Activity Relationships. J. Med. Chem. 1995, 38, 3226-3235.

46.Chen, Y. L.; Lu, C. M.; Chen, I. L.; Tsao, L. T.; Wang, J. P. Synthesis and Antiinflammatory evaluation of 9-Aminoacridin and 9-Phenoxyacridine Derivatives. J. Med. Chem. 2002, 45, 4689-4694.
47.Bar, G.; Parsons, A. F.; Thomas, C. B. Manganese(Ⅲ) Acetate Mediated Radical Reactions leading to araliopsine and related Quinoline Alkaloids. Tetrahedron. 2001, 57, 4719-4728.
48.Pirrung, M. C.; Blume, F. Rhodium-Mediated Dipolar Cycloaddition of Diazoquinolinediones. J. Org. Chem. 1999, 64, 3642-3649.
49.Svoboda, G. H.; Poore, G. E.; Simpson, P. J.; Boder, G. B. Alkaloids of Acronychia Baueri Schott Ⅰ. J. Pharm. Sci. 1996, 55, 758-768.
50.Wolter, B.; Eilert, U. Accunulation of Acridone-Epoxidea wih Fungi Cultures of Ruta Graveolens Increased by Mixed Culture with Fungi. Planta Med. 1981, 43, 166.
51.Chen, I. L.; Chen, Y. L.; Tzeng, C. C. Synthesis and Cytotoxic Evaluation of Some 4-Anilinofuro[2,3-b]quinoline Derivatives. Helv. Chm. Acta. 2002, 85, 2214-2221.
52.Li, J. H,; Serdruk, L.; Ferraris, D. V.; Synthesis of Substituted 5[H]Phenanthridin-6-ones as Potent Poly(ADP-ribose)polymerase-1 (PARP1) Inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1687-1690.
53.Schmidt, R. F. Ber. Dtsch. Ges. 1924, 57, 704.
第一頁 上一頁 下一頁 最後一頁 top